The University of Chicago Header Logo

Connection

Richard A. Larson to Translocation, Genetic

This is a "connection" page, showing publications Richard A. Larson has written about Translocation, Genetic.
Connection Strength

1.459
  1. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
    View in: PubMed
    Score: 0.191
  2. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1992 Apr 01; 79(7):1892-3.
    View in: PubMed
    Score: 0.098
  3. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15535-40.
    View in: PubMed
    Score: 0.077
  4. Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29.
    View in: PubMed
    Score: 0.076
  5. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
    View in: PubMed
    Score: 0.067
  6. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7.
    View in: PubMed
    Score: 0.065
  7. Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5.
    View in: PubMed
    Score: 0.064
  8. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15; 101(6):1420-7.
    View in: PubMed
    Score: 0.058
  9. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984 May; 76(5):827-41.
    View in: PubMed
    Score: 0.057
  10. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.056
  11. t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes Cancer. 2002 Jun; 34(2):186-92.
    View in: PubMed
    Score: 0.050
  12. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):395-400.
    View in: PubMed
    Score: 0.049
  13. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3070-5.
    View in: PubMed
    Score: 0.049
  14. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 01; 19(9):2482-92.
    View in: PubMed
    Score: 0.046
  15. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998 Oct 15; 92(8):2879-85.
    View in: PubMed
    Score: 0.039
  16. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer. 1997 Nov; 20(3):282-91.
    View in: PubMed
    Score: 0.036
  17. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
    View in: PubMed
    Score: 0.034
  18. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15.
    View in: PubMed
    Score: 0.031
  19. Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia. Cancer Res. 1994 Sep 15; 54(18):4999-5004.
    View in: PubMed
    Score: 0.029
  20. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993 Aug 01; 82(3):712-5.
    View in: PubMed
    Score: 0.027
  21. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 1993 Jun; 4(2):175-80.
    View in: PubMed
    Score: 0.027
  22. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.022
  23. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia. 1989 Dec; 3(12):866-70.
    View in: PubMed
    Score: 0.021
  24. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia. 1989 Jan; 3(1):42-7.
    View in: PubMed
    Score: 0.020
  25. Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders. Cancer Genet Cytogenet. 1989 Jan; 37(1):1-8.
    View in: PubMed
    Score: 0.020
  26. Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood. 1987 Nov; 70(5):1338-42.
    View in: PubMed
    Score: 0.018
  27. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986 Dec; 68(6):1242-9.
    View in: PubMed
    Score: 0.017
  28. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88.
    View in: PubMed
    Score: 0.014
  29. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004; 83 Suppl 1:S84-5.
    View in: PubMed
    Score: 0.014
  30. Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91.
    View in: PubMed
    Score: 0.013
  31. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
    View in: PubMed
    Score: 0.013
  32. Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer. 1982 Jun 01; 49(11):2222-5.
    View in: PubMed
    Score: 0.012
  33. Chromosome changes in hematologic malignancies. CA Cancer J Clin. 1981 Jul-Aug; 31(4):222-38.
    View in: PubMed
    Score: 0.012
  34. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics. 2000 Jul 01; 67(1):28-39.
    View in: PubMed
    Score: 0.011
  35. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995 Jan; 9(1):95-101.
    View in: PubMed
    Score: 0.007
  36. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.007
  37. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.006
  38. Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU. Invest New Drugs. 1988 Jun; 6(2):121-4.
    View in: PubMed
    Score: 0.005
  39. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.